Treatment of Migraine with Aura in Comorbid Depression, Anxiety Disorder, Epilepsy, or Arterial Hypertension
When migraine with aura occurs alongside a significant comorbid condition, the choice of preventive management must be tailored to that coexisting diagnosis. A one-size approach is insufficient: the comorbidity shapes which interventions are appropriate.
Clinical Scenario
This protocol applies to patients with migraine with aura who also carry a diagnosis of depression, anxiety disorder, epilepsy, or arterial hypertension. Each of these comorbidities has direct implications for which preventive therapy is selected — agents beneficial for one comorbidity may be inappropriate or less suitable in another.
Treatment Approach
Preventive therapy is chosen based on the specific comorbidity present — different drug classes are indicated depending on whether the co-occurring condition involves mood, anxiety, seizure disorder, or blood pressure. The complete selection criteria, preferred agents, and alternatives are set out in the full protocol.
References
- If comorbid depression is present in migraine, amitriptyline (75–150 mg) should be administered as drug of first choice, or alternatively venlafaxine (150–225 mg).
- In comorbid anxiety disorder, amitriptyline or venlafaxine are recommended.
- Epilepsy occurs more often in patients with than without migraine: topiramate and valproic acid are the drugs of choice for prevention.
- In secondary vascular diseases (stroke, coronary heart disease), the patient’s risk profile should be considered in the choice of migraine prevention (e.g. candesartan in arterial hypertension).
DOI: 10.1177/2514183X1882337
View source ↗